OrbiMed Capital GP VII LLC's Net Worth

$384 Million

Who is OrbiMed Capital GP VII LLC?

OrbiMed Capital GP VII LLC has an estimated net worth of $384 Million. This is based on reported shares across multiple companies, which include Keros Therapeutics, Inc., Fusion Pharmaceuticals Inc., Repare Therapeutics Inc., Arcutis Biotherapeutics, Inc., Theseus Pharmaceuticals, Inc., Kinnate Biopharma Inc., Sierra Oncology, Inc., Synthorx, Inc., Terns Pharmaceuticals, Inc., Galecto, Inc., Passage BIO, Inc., Enliven Therapeutics, Inc., Janux Therapeutics, Inc., Third Harmonic Bio, Inc., and Pandion Therapeutics Holdco LLC.

SEC CIK

OrbiMed Capital GP VII LLC's CIK is 0001760648

Past Insider Trading and Trends

2020 was OrbiMed Capital GP VII LLC's most active year for acquiring shares with 36 total transactions. OrbiMed Capital GP VII LLC's most active month to acquire stocks was the month of December. 2023 was OrbiMed Capital GP VII LLC's most active year for disposing of shares, totalling 37 transactions. OrbiMed Capital GP VII LLC's most active month to dispose stocks was the month of March. 2020 saw OrbiMed Capital GP VII LLC paying a total of $106,373,691.00 for 30,545,108 shares, this is the most they've acquired in one year. In 2022 OrbiMed Capital GP VII LLC cashed out on 17,526,737 shares for a total of $133,513,360.13, their largest year based on trade value.